Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin versus duloxetine for overactive bladder in women
IRCT20191010045047N1Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Oct 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of solifenacin and duloxetine in overactive bladder (OAB) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Bladder disease status and Drug side effects. Started Oct 2019; status: completed.
02
Drugs
solifenacinduloxetine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on IRCT20191010045047N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191010045047N1.